Younger age at onset of sporadic Parkinson's disease among subjects occupationally exposed to metals and pesticides

Interdisciplinary Toxicology

Volumn 7, Issue 3, 2014, Pages 122-133

  Ratner, Marcia H ^a   Farb, David H ^a   Ozer, Josef ^a   Feldman, Robert G ^a   Durso, Raymon ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

age; metals; Occupational exposure; onset; Parkinson's disease; pesticides

Indexed keywords

METAL; PESTICIDE;

ADULT; AGED; ARTICLE; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENETIC RISK; HEAD INJURY; HEREDITY; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; ONSET AGE; PARKINSON DISEASE; SMOKING; VERY ELDERLY;

EID: 84921351493     PISSN: 13376853     EISSN: 13379569     Source Type: Journal    
DOI: 10.2478/intox-2014-0017     Document Type: Article

References (64)

1. Ahmadi A, Fredrikson M, Jerregard H, Akerback A, Fall PA, Rannug A, Axelson O, Soderkvist P. (2000). GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. Biochem Biophysiol Res Comm 269(3): 676-680.
2. Andersen JK (2003) Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease. Neurotoxicol Res 5(5): 307-313.
3. Ascherio A, Chen H, Weisskopf MG, O'reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ. (2006). Pesticide exposure and risk for Parkinson's disease. Ann Neurol 60(2): 197-203
4. Barbeau A, Roy M, Bernier G, Campanella G, Paris S. (1987). Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci 14(1): 36-41.
5. Beal MF. (2003). Mitochondria, oxidative damage, and infl ammation in Parkinson's disease. Ann N Y Acad Sci 991: 120-131.
6. Calne S, Schoenberg B, Martin W, Uitti RJ, Spencer P, Calne DB. (1987). Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 14(3): 303-305.
7. Dawson TM, Dawson VL. (2003). Molecular pathways of neurodegeneration in Parkinson's disease. Science 302(5646): 819-822.
8. DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH. (2002). PARK3 infl uences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Human Gen 70(5): 1089-1095.
9. Di Llio C, Sacchetta P, Iannarelli V, and Aceto A. (1995). Binding of pesticides to alpha, mu and pi class glutathione transferase. Toxicol Letters 76(2): 173-177.
10. Dobson AW, Erikson KM, Aschner M. (2004). Manganese neurotoxicity. Ann NY Acad Sci 1012: 115-128.
11. Feldman RG, and Ratner MH. (1999). The pathogenesis of neurodegenerative disease: neurotoxic mechanisms of action and genetics. Cur Opin Neurol 12(6): 725-731.
12. Fidler AT, Baker EL, Letz RE. 1987. Estimation of long-term exposure to mixed solvents from questionnaire data: a tool for epidemiological investigations. Brit J Ind Med 44(2): 133-141.
13. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R. (1996). Inhibition of monoamine oxidase B in the brains of smokers. Nature 379(6567): 733-736.
14. Ghione I, Di Fonzo A, Saladino F, Del Bo R, Bresolin N, Comi GP, Rango M. (2007). Parkin polymorphisms and environmental exposure: decrease in age at onset of Parkinson's disease. Neurotoxicology. 28(3): 698-701.
15. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. (1997). Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 48(3): 650-8.
16. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. 1998. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50(5): 1346-1350.
17. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. (1999). Smoking and Parkinson's disease: a dose-response relationship. Neurology 52: 115-119.
18. Gu Z, Feng X, Dong X, Chan P. (2010). Smoking, genes encoding dopamine pathway and risk for Parkinson's disease. Neurosci Lett. 482(1): 31-34.
19. Gudelsky GA, Yamamoto BK. (2003). Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine. Methods Mol Med 79: 55-73.
20. Hane M, Axelson O, Blume J, Hogstedt C, Sundell L, Ydreborg B. (1977). Psychological function changes among house painters. Scand J Work Environ Health 3(2): 91-99.
21. Hassoun E, Bagchi M, Bagchi D, Stohs SJ. (1993). Comparative studies on lipid peroxidation and DNA-single strand breaks induced by lindane, DDT, chlordane and endrin in rats. Comp Biochem Physiol 104(3): 427-431.
22. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. (2001). Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 50(6): 780-786.
23. Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, Meng C, Marras C, Korell M, Kasten M, Hoppin JA, Comyns K, Chade A, Blair A, Bhudhikanok GS, Webster Ross G, William Langston J, Sandler DP, Tanner CM. (2014) Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat Disord. 20(1): 82-7.
24. Khalil AA, Davies B, Castagnoli N Jr. (2006). Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorg Med Chem. 14(10): 3392-3398.
25. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676): 605-608.
26. Klawans HL Jr, Cohen MM. (1970). Diseases of the extrapyramidal system. Dis Mon Feb: 1-52.
27. Koller WC, Lyons KE, Truly W. (2004). Eff ect of levodopa treatment for parkinsonism in welders: A double-blind study. Neurology 62(5): 730-733.
28. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. (1999). Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 52(2): 302-308.
29. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. (2002). Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 277(7): 5411-5417.
30. Leroy E, Boyer R, Polymeropoulos MH. (1998). Intron-exon structure of ubiquitin c-terminal hydrolase-L1. DNA Research 5(6): 397-400.
31. Lindstrom K, Martelin T. (1980). Personality and long-term exposure to organic solvents. Neurobehav Toxicol 2(2): 89-100.
32. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. (1997). Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 48(6): 1583-1588.
33. Lücking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefl e P, Wood NW, Agid Y, Brice A. (2000). Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342(21): 1560-1567.
34. Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH. (2002). Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology 58(7): 79-84.
35. McDonnell L, Maginnis C, Lewis S, Pickering N, Antoniak M, Hubbard R, Lawson I, Britton J. (2003). Occupational exposure to solvents and metals and Parkinson's disease. Neurology 61(5): 716-717.
36. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. (1998). Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352(9137): 1344-1346.O
37. 'Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, Ascherio A. (2005). Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord. 20(10): 1383-1384.
38. Peng J, Mao XO, Stevenson FF, Hsu M, Andersen JK. (2004). The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J Biol Chem 279(31): 32626-32632.
39. Periquet M, Lücking C, Vaughan J, Bonifati V, Durr A, De Michele G, et al. (2001). Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder eff ects. Am J Hum Genet 68(3): 617-626.
40. Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, Masaki KH, Blanchette PL, Popper JS, Foley D, Launer L, White LR. (2002). Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 59(11): 1787-1792.
41. Pezzoli G, Canesi M, Antonini A, Righini A, Perbellini L, Barichella M, Mariani CB, Tenconi F, Tesei S, Zecchinelli A, Leenders KL. (2000). Hydrocarbon exposure and Parkinson's disease. Neurology 55(5): 667-673.
42. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. (1997). Mutation in the alpha-synuclein gene identifi ed in families with Parkinson's disease. Science 276(5321): 2045-2047.
43. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. (2000). A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 21(4): 435-440.
44. Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS. (2001). Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 56(1): 8-13.
45. Rajput AH, Uitti RJ, Stern W, Laverty W, O'Donnell K, O'Donnell D, Yuen WK, Dua A. (1987). Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci 14: 414-418.
46. Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E. 1996. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46(5): 1275-1284.
47. Seppalainen AM, Lindstrom K, Martelin T. (1980). Neurophysiological and psychological picture of solvent poisoning. Am J Ind Med 1(1): 31-42.
48. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. (2003). Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23(34): 10756-10764.
49. Singh NK, Banerjee BD, Bala K, Basu M, Chhillar N. (2014) Gene-Gene and Gene-Environment Interaction on the Risk of Parkinson's Disease. Curr Aging Sci. [Epub ahead of print]
50. Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. (1998). A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology 19(4-5): 709-712.
51. Smargiassi A, Mutti A. (1999). Peripheral biomarkers and exposure to manganese. Neurotoxicology 20(2-3): 401-406.
52. Sukata T, Uwagawa S, Ozaki K, Ogawa M, Nishikawa T, Iwai S, Kinoshita A, Wanibuchi H, Imaoka S, Funae Y, Okuno Y, Fukushima S. (2002). Detailed lowdose study of 1,1-bis(p-chlorophenyl)-2,2,2-trichloroethane carcinogenesis suggests the possibility of a hormetic eff ect. Int J Cancer 99(1): 112-118.
53. Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, Chung H, Shen H, Zhao Y, Teoh ML, Yih Y, Pavanni R, Chandran VR, Wong MC. (2003). Dose-dependent protective eff ect of coff ee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 216(1): 163-167.
54. Tanner CM, Goldman SM. (1996) Epidemiology of Parkinson's disease. Neurol Clin 14(2): 317-335.
55. Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, Langston JW. (2002). Smoking and Parkinson's disease in twins. Neurology 58: 581-588.
56. Tanner CM, Goldman SM, Ross GW, Grate SJ. (2014) The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk. Alzheimers Dement. 10(3 Suppl): S213-25.
57. Taylor CA, Saint-Hilaire MH, Cupples LA, Thomas CA, Burchard AE, Feldman RG, Myers RH. (1999). Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. Am J Med Gen 88: 742-749.
58. Thiruchelvam MJ, McCormack A, Richfi eld EK, Baggs RB, Tank AW, Di Monte DA, Cory-Slechta DA. (2003). Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 18(3): 589-600.
59. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK. (2004). Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 19(4): 845-854.
60. Twelves D, Perkins KS, Counsell C. (2003). Systematic review of incidence studies of Parkinson's disease. Mov Disord 18(1): 19-31.
61. Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, Stoof JC. (1994). The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord 9(6): 664-672.
62. Ward CD, Gibb WR. (1990). Research diagnostic criteria for Parkinson's disease. Adv Neurol 53: 245-249.
63. Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, et al. (2006) Herbicide exposure modifi es GSTP1 haplotype association to Parkinson onset age: the Gene PD Study. Neurology 67(12): 2206-2210.
64. Wu MT, Pan CH, Huang YL, Tsai PJ, Chen CJ, Wu TN. (2003). Urinary excretion of 8-hydroxy-2-deoxyguanosine and 1-hydroxypyrene in coke-oven workers. Environ Mol Mutagen 42(2): 98-105.